Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.5362
-0.0051-0.94%
Post-market: 0.53900.0028+0.52%19:47 EDT
Volume:3.47M
Turnover:1.84M
Market Cap:127.40M
PE:-1.43
High:0.5500
Open:0.5312
Low:0.5118
Close:0.5413
Loading ...

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Jun

Sangamo Biosciences (SGMO) Receives a Buy from H.C. Wainwright

TIPRANKS
·
25 Jun

Sangamo Therapeutics Says Phase 1/2 Fabry Disease Study Showed Favorable Safety Profile; Shares Up Pre-Bell

MT Newswires Live
·
24 Jun

BRIEF-Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Reuters
·
24 Jun

Sangamo Therapeutics Receives Key FDA Designations and Advances Towards 2026 BLA Submission for Fabry Disease Gene Therapy

Reuters
·
24 Jun

Sangamo Therapeutics Inc - to Submit Bla in 2026

THOMSON REUTERS
·
24 Jun

Sangamo Therapeutics Inc - Isaralgagene Civaparvovec Shows Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
24 Jun

Sangamo Therapeutics Inc - STAAR Study Shows Positive Mean Annualized Egfr Slope at 52 Weeks

THOMSON REUTERS
·
24 Jun

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

THOMSON REUTERS
·
24 Jun

Sangamo Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
17 Jun

Sangamo Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
14 May

Truist Financial Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

TIPRANKS
·
14 May

Top Premarket Decliners

MT Newswires Live
·
13 May

Sangamo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BRIEF-Sangamo Therapeutics Q1 EPS USD -0.14 Vs. IBES Estimate USD -0.13

Reuters
·
13 May

Sangamo Therapeutics Reports Q1 2025 Net Loss of $30.6 Million, Down from $49.1 Million in 2024; EPS Improves to $0.14 Loss from $0.27

Reuters
·
13 May

Sangamo Therapeutics Q1 Operating Expenses USD 36.1 Million

THOMSON REUTERS
·
13 May

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

THOMSON REUTERS
·
13 May

Sangamo Therapeutics Launches $23 Million Share Offering with Warrants Priced at $0.50 Each

Reuters
·
13 May

Press Release: Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Dow Jones
·
13 May